AFP and hepatocellular carcinoma: In addition, patients with advanced-stage hepatocellular carcinomas had significantly higher median AFP serum levels (BCLC B/C) than that of early-stage tumors (BCLC 0/A) (300 ng/mL versus 17 ng/mL, P = 0.0014).